Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-Resistance With Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-1169
Full Text
Open PDFAbstract
Available in full text
Date
July 19, 2016
Authors
Publisher
American Association for Cancer Research (AACR)